Covance and BML, Inc. have expanded their Covance-BML Clinical Trial Laboratory (CB Trial Lab) in Kawagoe City, Saitama Prefecture. The companies opened the lab in 2010 as part of a five-year agreement and will launch several new services this month.
“The expansion of the CB Trial Lab speaks to both the success of our affiliation with BML and the growing drug development relationships we have built with our clients in Japan and across the Asia-Pacific region,” said Jonathan Koch, global general manager, Covance Central Laboratory Services.
“This investment is an important step in growing our relationship with Covance and allows us to offer clients a wider range of services in an increasingly competitive marketplace,” said Kazuta Fukuda, president of BML.
The lab expansion includes a 50% increase in the size of the facility, as well as new testing platforms, equipment and additional sample storage space. New service offerings have been added in the areas of immunoassay, flow cytometry, and protein chemistry. The CB Trial Lab is CAP accredited and maintains CDC lipid certification as well as National Glycohemoglobin Standardization Program (NGSP).